Patient Recruitment Applications & Studies

91. Ulcerative Colitis Study Gets Back On Track With Recruitment Support In Four Countries 6/30/2021

    A global biotech initiated a phase IIb orphan drug study for the treatment of chronic ulcerative colitis. After deploying traditional recruitment methods, the sponsor met only 60% of its patient enrollment target, and extended the recruitment window an additional six months. Finding the right partner allowed them to successfully close the enrollment gap and move the study forward as planned.

92. Retention And Compliance In A Multicenter, Open-Label Clinical Trial 6/18/2021

    Missing outcome data caused by patient dropout and poor compliance not only jeopardize the scientific validity of a study, but also come at a significant financial cost to study sponsors. Technology and behavioral science offer potential solutions that together can address these challenges through patient-centric design of tools. This case study examines retention and compliance in a multicenter, open-label clinical trial (N=36) with the use of the Linkt mobile application.

93. Overcoming EU Recruitment Challenges 6/14/2021

    A biotech client needed to conduct a challenging Phase III study, requiring fast recruitment from multiples sites across Europe. This case study outlines how we achieved the Pan-European recruitment target on time to deliver the study successfully.

94. The Case For Patient Diversity In Clinical Trials 2/25/2021

    Uncover how a global pharmaceutical company met the FDA's challenge to increase patient diversity with a multi-tiered approach combining key tactics and technology.

95. Groundbreaking Work Leads To First Gene Therapy Ever Approved In Europe 1/14/2021

    Veristat was brought in to create and manage a full development program for a gene therapy for a very rare inherited disorder. The work involved charting the course in completely uncharted waters – our team had to create industry best practices that didn’t exist before, anywhere. With no classic route to market, Veristat’s experts wrote the map on patient recruitment, regulatory and health agency engagement, natural history studies and the Central Site Model.

96. Rho's Approach To Overcoming Enrollment Challenges In A CNS Trial 1/7/2021

    A mid-sized biotech company running a randomized, doubleblind, placebo controlled (1:1) Phase 3 CNS pain study, with a single treatment administration, had achieved ex-US approval yet faced significant enrollment challenges when a modified version of the study was implemented in the US. With a goal of 300 participants, the rate of enrollment sat at a mere 0.5 subjects a month. The best laid plans weren’t cutting it.

97. How Ramping Up Communications Helped Overcome A Next-To-Impossible Recruitment Challenge 4/21/2020

    We knew going in that it could be the perfect recruiting nightmare with extremely complex inclusion/exclusion criteria. By letting sites set their own goals and commit to them along with assigning project coordinators that stayed close to those sites the study is off to a good start.

98. From KOLs To Patient Advocates, Using Every Tool To Fight A Rare Disease 3/11/2020

    With a recruiting target of 18 patients for a condition that afflicts just one in 31,000 people this CRO had to make full use of what few resources were avaiable. By working with KOLs and a patient advocacy group they located their 18 patients ahead of schedule and completed the 26-week trial early.

99. A High Unmet Need That No One Wanted To Talk About 3/2/2020

    What do you do when patients are too embarrassed to talk about what’s wrong with them? Recruiting “hidden” patient groups for rare disease studies is always challenging, and flexibility is the only constant.

100. Clinical Trial Start To Finish …. That Was Easy 2/26/2020

     A sponsor needed to test a new nonsteroidal anti-inflammatory drug (NSAID). Working with an experienced CRO allowed them to line up the 40 best sites in the country for this type of analgesia study and have the best training and tools at each site.